Hellebrigenin, one of
bufadienolides belonging to cardioactive
steroids, was found in skin secretions of toads and plants of Helleborus and Kalanchoe genera. In searching for natural constituents with anti-
hepatoma activities, we found that
hellebrigenin, isolated from
traditional Chinese medicine Venenum Bufonis, potently reduced the viability and colony formation of human
hepatocellular carcinoma cells HepG2, and went on to explore the underlying molecular mechanisms. Our results demonstrated that
hellebrigenin triggered DNA damage through
DNA double-stranded breaks and subsequently induced cell cycle G2/M arrest associated with up-regulation of p-ATM (Ser(1981)), p-Chk2 (Tyr(68)), p-CDK1 (Tyr(15)) and
Cyclin B1, and down-regulation of p-CDC25C (Ser(216)). It was also found that
hellebrigenin induced mitochondrial apoptosis, characterized by Bax translocation to mitochondria, disruption of mitochondrial membrane potential, release of
cytochrome c into cytosol and sequential activation of
caspases and PARP. In addition, Akt expression and phosphorylation were inhibited by
hellebrigenin, whereas Akt silencing with
siRNA significantly blocked cell cycle arrest but enhanced apoptosis induced by
hellebrigenin. Activation of Akt by human
insulin-like growth factor I (hIGF-I) could obviously attenuate
hellebrigenin-induced cell death. In summary, our study is the first to report the efficacy of
hellebrigenin against HepG2 and elucidated its molecular mechanisms including DNA damage, mitochondria collapse, cell cycle arrest and apoptosis, which will contribute to the development of
hellebrigenin into a chemotherapeutic agent in the treatment of
liver cancer.